A GMMA-CPS-Based Vaccine for Non-Typhoidal Salmonella

Posted on by

AUTHORS

Akosiererem S Sokaribo, Sumudu R Perera, Zoe Sereggela, Ryan Krochak, Lindsay R Balezantis, Xiaohui Xing, Shirley Lam, William Deck, Sam Attah-Poku, Dennis Wade Abbott, Shantanu Tamuly, Aaron P White

ABSTRACT

Non-typhoidal Salmonella are a major cause of gastroenteritis worldwide, as well as causing bloodstream infections in sub-Saharan Africa with a high fatality rate. No vaccine is currently available for human use. Current vaccine development strategies are focused on capsular polysaccharides (CPS) present on the surface of non-typhoidal Salmonella. This study aimed to boost the amount of CPS purified from S. Typhimurium for immunization trials. Random mutagenesis with Tn10 transposon increased the production of CPS colanic acid, by 10-fold compared to wildtype. Immunization with colanic acid or colanic acid conjugated to truncated glycoprotein D or inactivated diphtheria toxin did not induce a protective immune response in mice. However, immunization with Generalized Modules for Membrane Antigens (GMMAs) isolated from colanic acid overproducing isolates reduced Salmonella colonization in mice. Our results support the development of a GMMA-CPS-based vaccine against non-typhoidal Salmonella.

Click here to read the article, published in Vaccines.